tbuckley/cabot-search huggingface dataset:
Prediction of long-term survival conditional on years survived following nephrectomy
Authors: M. A. Laudano, M. Desai, K. K. Badani, A. L. Hirsh, M. C. Benson, J. M. McKiernan
Journal: Journal of Clinical Oncology (2008)

5120 Background: In counseling patients after nephrectomy for renal cell carcinoma (RCC), the current literature estimates a 5-year survival probability based on clinical and pathologic parameters. However, patients are not given an updated survival probability as a function of time. We examined changes in 5 and 10-year survival probabilities conditional on years survived post-surgery and evaluated the effect of metastasis and local recurrence (LR) on these probabilities. Methods: Using the Columbia Clinical Database of Urologic Oncology, 1114 partial and radical nephrectomy patients for RCC from 1998 to 2007 were analyzed. Based on a Cox proportional hazards model, conditional probabilities were calculated for each year survived post-surgery adjusting for standard variables (age at surgery, Fuhrman grade, pathologic stage, tumor size, lymph node status, and vascular invasion, necrosis). To incorporate change in recurrence-free status over time, a series of Landmark analyses were performed for the following groups: disease-free, LR, metastasis, and both. Results: The baseline 5-year overall survival probability was 0.78. Conditional on surviving 1 year post-surgery, this probability increases to 0.81 and reaches 0.96 for those who survive 4 years. Disease-specific survival increases from baseline 0.87 to 0.90 and 0.99 over the same time period. Baseline 10-year overall survival estimate is 0.54, once 1, 3, and 7 years are survived, the probability increases to 0.56, 0.63, and 0.78, respectively. In landmark analyses of patients who remain disease-free, 5-year survival ranges from 0.88 to 0.95 after conditioning on surviving 1 to 4 years, respectively. With LR, the 5-year survival ranges from 0.65 to 0.76 after conditioning on surviving 1 to 4 years. With metastasis, the 5-year survival ranges from 0.53 to 0.89 after conditioning on surviving 1 to 4 years. Only 3 patients experienced both metastasis and LR and none survived 5 years. Conclusions: Our study shows that survival estimates increase significantly as the number of years survived increases, and the probability relates to the development of LR and metastasis. Determining conditional survival estimates has implications for counseling patients and implementing effective post-operative surveillance protocols. No significant financial relationships to disclose.
Influence of anthracycline- and/or taxane-based chemotherapy on bone metabolism of patients with primary breast cancer
Authors: C.M. Kurbacher, N. Rauschenbach, A.T. Kurbacher, S. Herz, K. Monreal, C. Bartling, J.A. Kurbacher, A. Quade
Journal: Annals of Oncology (2015)
Abstract 16847: C-kit+ Cells Restore Podocyte Function in a Model of Acute Glomerulonephritis in Rats
Authors: Erika Bevilaqua Rangel, Samirah Abreu Gomes, Rosemeire Kanashiro-Takeuchi, Phillip Ruiz, Jochen Reiser, Joshua M Hare
Journal: Circulation (2013)

Introduction: Kidney-derived c-kit cells exhibit the properties of stem cells and regenerate epithelial tubular cells following ischemia-reperfusion injury. We hypothesize that c-kit+ cells have th...
Aging and cancer.
Authors: B J Kennedy
Journal: Journal of Clinical Oncology (1988)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1988.6.12.1903 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3058879 Aging and cancer. B J KennedyxB J KennedySearch for articles by this author Show More University of Minnesota Medical School, Minneapolis 55455. https://doi.org/10.1200/JCO.1988.6.12.1903 First Page PDF © 1988 by American Society of Clinical Oncology
Tumor-Graft Rejection in Syngeneic Guinea Pigs: Evidence for a Two-Step Mechanism
Authors: Berton Zbar, Harold T. Wepsic, Tibor Borsos, Herbert J. Rapp
Journal: JNCI Journal of the National Cancer Institute (1970)

The growth of a transplantable strain-2 hepatoma was suppressed at the site of delayed hypersensitivity skin reactions to another, antigenically different, transplantable strain-2 hepatoma and at the site of delayed hypersensitivity skin reactions to bacterial antigens. The ability to kill antigenically unrelated tumor cells by delayed hypersensitivity skin reactions could be transferred from sensitized donors to unimmunized recipients by means of peritoneal exudate cells. Close contact between sensitized cells, sensitizing antigen, and the antigenically unrelated tumor cells was required to suppress growth of the antigenically unrelated tumor cells. Tumor-graft rejection occurring without delayed hypersensitivity skin reactions did not cause suppression of antigenically unrelated tumor cells.
Effect of subcutaneous amifostine administration on systolic blood pressure in patients receiving daily fractionated radiotherapy
Authors: R. C. Nichols, H. R. Henderson, S. K. Mahmood, F. C. Malamud
Journal: Journal of Clinical Oncology (2004)

8176 Background: Acute hypotension is recognized as a potential complication of intravenous and subcutaneous amifostine administration. This study was undertaken to assess the degree and severity of changes in systolic blood presssure (SBP) after the daily subcutaneous administration of 500mg of amifostine prior to the delivery of fractionated external beam radiotherapy. Methods: From 03/2002 through 03/2003, 20 patients with primary head and neck (12) or non-small cell lung (8) cancers received a total of 350 subcutaneous amifostine administrations. Patients received a mean of 17.5 and a median of 18 doses over their planned course of radiotherapy. Patients were advised to consume 16 ounces of water or other clear liquid two hours prior to amifostine administration. Patients were advised to continue their previously prescribed blood pressure medications. Blood pressure readings were taken prior to each injection. The injection of amfostine was withheld if SBP was felt to be inadequate. Three follow up blood pressure readings were taken within 30 minutes after the subcutaneous injections. Results: No patient suffered a significant hypotensive episode requiring IV fluid administration or other remedial intervention. Mean and median SBP declines were 12.4mmHg and 12mmHg respectively for all injections delivered. The greatest single decline in SBP seen was 42mmHg, however 90% of all declines in SBP were less than 25mmHg. Conclusions: The current study demonstrates the safety and feasibility of subcutaneous amifostine administration in the setting of daily fractionated radiotherapy. The data presented may be used to roughly predict the expected post-injection SBP in patients receiving subcutaneous amifostine in this dose range. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Mediumne (Nichols)
Properties of the Common Antigen Associated With Marek's Disease Herpesvirus and Turkey Herpesvirus Infections
Authors: M. Onuma, T. Mikami, T. T. A. Hayashi
Journal: JNCI Journal of the National Cancer Institute (1974)

An agar-gel precipitation (AGP) antigen prepared from feather tips (feather-prep) of chickens infected with Marek's disease herpesvirus (M DHV), and 4 antigens from cell extracts (cell-prep) or culture fluids (fluid-prep) of cultures infected with either MDHV or herpesvirus of turkeys (HVT) had 1 precipitation line in common. The common antigen was stable at 50° C, but not 60°, for 30 minutes, unstable at pH 10.5 or above, or pH 2.5 or below, and remained in the aqueous phase after centrifugation at 100,000×g for 90 minutes. It was unaffected by acetone and ether, but was partially destroyed by pronase and completely by sodium period ate. The molecular weight, estimated by gel filtration, isoelectric point, and sedimentation velocity of the feather-prep, was 33,000 ± 5000 dalton, pl 6.35 and 4.25, respectively, whereas the molecular weights of MDHV- and HVT-fluid-prep were 46,000 ± 8000 and 43,000 ± 6000 dalton, respectively, and the isoelectric point of both preparations was pl 4.5. By sucrose-gradient (12-52%) centrifugation of the supernatant of disrupted cells, the common antigen was separated from the virus particles. The common antigen contained no virus particles and formed 1 AGP line. However, the concentrated materials of pooled fractions containing virus particles formed 2 lines, one of which fused to that of the common antigen. These find ings suggest that the common antigen obtained from the cells with MDHV or HVT was a glycoprotein. The possibility that the common antigen was associated with the envelope of the virus was discussed.
A phase II study of docetaxel (T) and capecitabine (X) combination chemotherapy as first-line chemotherapy for patients (pts) with metastatic breast cancer (MBC)
Authors: H.-S. Lim, H. G. Lee, J. H. Chun, J. J. Lee, J. S. Lee, J. Ro
Journal: Journal of Clinical Oncology (2005)

889 Background: The addition of X to T extends survival, time to disease progression (TTP) and response rate (RR) in pts with pretreated MBC. This phase II study evaluated the efficacy and safety of TX as a first-line therapy for pts with stage IV or recurrent breast cancer. Methods: Eligible pts had measurable MBC, ECOG PS of 0–2 and had received no prior chemotherapy for metastasis. Pts received T 75mg/m2 i.v. with routine premedication on day 1 and X 1000mg/m2 p.o. bid on days 1–14, q 3 weeks until disease progression or unacceptable toxicity. Results: Of the 38 pts enrolled, 5 are not evaluable (2 ineligible and 3 lost to follow up after 1 cycle). Of the 33 evaluable pts, 21 had recurrent and 12 stage IV disease with median age of 52 yrs (range 28–68). ER+ was 36%, PR+ 30%, HER2 3+ 18%. Disease free interval for recurrent disease was 24 mo (range 5–96). Metastatic site: lymph nodes (76%), breast (52%), bone (36%), liver (33%), lung (27%), and skin (9%). Previous adjuvant chemotherapy: anthracycline-based (29%); CMF (67%). A total of 178 cycles with median 6 (range 2–10) per pt were given. The mean relative dose intensities for T and X were 85% and 75%, respectively. Adverse event: G3/4 neutropenia (82%, febrile 3%), G3 hand-foot syndrome (12%), and G2 nail changes (79%). There was no treatment-related death. The overall RR was 61% (3 CRs and 17 PRs). RR was significantly higher in pts without prior adjuvant chemotherapy (85% vs. 45%; p=0.02). All 3 CRs and 15/17 PRs were observed in anthracycline-naïve pts. Median TTP was 8.4 mo (95% CI, 7.0–10.9) and median response duration was 7.4 mo (95% CI, 6.6–16.5). After a median follow up of 20.0 mo (range 3.3–27.7), 10 pts died and median survival has not been reached. Conclusion: TX is highly active as first-line therapy for pts with MBC, with a durable TTP and high RR, particularly in pts having received no anthracyclines in adjuvant setting. The rate of G3/4 neutropenia was high, but would likely be reduced through appropriate T dose reductions. (Supported in part by Aventis and Roche Korea) No significant financial relationships to disclose.
Phase I study of the combination of anti-GD2 antibody 3F8 and barley-derived (1→3,1→4)-β-D-glucan for patients with resistant neuroblastoma
Authors: S. Modak, B. H. Kushner, K. Kramer, A. Vickers, N. Cheung
Journal: Journal of Clinical Oncology (2007)

9566 Background: Beta glucans are complex, naturally occurring polysaccharides that prime leucocyte dectin and CR3 receptors. Based on our preclinical observations that oral barley-derived (1→3,1→4)-β-D-Glucan (BG) synergizes with the murine anti-GD2 antibody 3F8 against neuroblastoma (NB) (Clin Cancer Res 8:1217), we conducted a phase I study to determine the safety of the combination of BG and 3F8 in patients with resistant NB. Methods: Heavily pre-treated patients with recurrent or refractory advanced stage NB were treated with 3F8/BG. Each cycle consisted of intravenous (IV) 3F8 at a fixed dose of 10 mg/m 2 /day ×10 days, plus oral BG dose escalated from 10 to 80 mg/kg/day ×10 days in 4 cohorts of 6 patients each. Patients without human anti-mouse antibody (HAMA) could be re-treated up to a total of 4 cycles. Results: Twenty-three patients with stage 4 and one with stage 3 NB (M:F = 11:13; median age 8 (range 2–19) years completed 47 cycles of therapy with 3F8/BG. 8 patients had progressive disease (PD) while 16 had stable refractory NB (SD) at enrollment. All patients completed at least one cycle of therapy and were evaluated for toxicity and response. Maximum tolerated dose for BG was not reached. Two patients developed dose-limiting toxicities (DLT). Both had grade 4 thrombocytopenia after completing one cycle of treatment: one at BG dose of 20mg/kg/day and the other at 40 mg/kg/day. Both cases responded to therapy with a short course of ITP (idiopathic thrombocytopenic purpura) therapy; one subsequently developed chronic ITP. There were no other &gt;grade 2 toxicities related to 3F8/BG therapy. 14, 4, 2 and 6 patients completed 1, 2, 3 and 4 cycles respectively. Reasons for withdrawal in patients who did not complete 4 cycles were PD in 10, persistently elevated HAMA in 6 and DLT in 2. Overall 11 patients had SD and 13 PD. 14/23 patients with positive MIBG scans prior to therapy demonstrated improvement after one cycle. Responses did not correlate with BG dose received. 7 patients, all with residual disease survive at a median of 40 (range 24–45) months post-treatment. Conclusions: 3F8/BG is well tolerated and shows activity against resistant NB. Further clinical investigation of this novel combination is warranted. No significant financial relationships to disclose.
Efficacy of chemotherapy after treatment with regorafenib in metastatic colorectal cancer (mCRC).
Authors: Michael Todd Kidd, Ryan Eldredge Wilcox, Jane Rogers, Cathy Eng, Siamak Saadat, Heinz-Josef Lenz, Joleen Marie Hubbard, Axel Grothey
Journal: Journal of Clinical Oncology (2015)

678 Background: Improvements in outcome of medical therapy for mCRC are closely linked to availability of active agents. Based on phase III clinical data, regorafenib, a multikinase inhibitor, received FDA approval September 2012 for patients with mCRC previously treated with all approved therapies. Post regorafenib therapy (PRTx) has not been established. Based on clinical observations, we established a multi-institution collaboration to assess chemotherapy response in mCRC after regorafenib therapy. Methods: After IRB approval, patient records at Mayo Clinic (MC), MD Anderson (MDA) and the University of Southern California (USC) from April 2010 to February 2014 were reviewed for regorafenib use and outcomes for mCRC. Therapies, patient and tumor characteristics were reviewed. Response and progression were determined by investigator review. Kaplan-Meier method was used to calculate survival. Results: Regorafenib was given to 173 patients with mCRC (MC:59 MDA:95 and USC:19). Of these, 11 (6%) continued on regorafenib at time of analysis and 98 (57%) received no additional therapy. PRTx was given to 64 (37%) patients, 31 of which went on a clinic trial. 33 patients were treated with standard approved therapy of which 11 (33%) progressed, 20 (61%) showed response or SD, and 2 (6%) were not evaluable. Out of the 33 treated with standard agents, 8 (24%) had stable disease or response to a treatment previously discontinued without definitive PD, whereas 4 (12%) responded to rechallenge with chemotherapy previously discontinued due to PD. Response was noted in 8 (24%) patients that received an agent not given prior to regorafenib. After discontinuation of regorafenib, mOS was 6.5 mo (CI 4.9 – 9.4), and the probability of survival at 6 and 12 months was 52% and 27% respectively. Conclusions: With the caveat of a small sample size and a potential selection bias, our multi-institution study shows that re-utilizing standard treatment options after regorafenib may be beneficial in select patients with mCRC including in patients with progression on identical therapy before regorafenib. Further retrospective and prospective studies could be warranted to define the role of regorafenib as a chemotherapy re-sensitizing agent.
An outbreak of Salmonella Typhimurium traced back to salami, Denmark, April to June 2010
Authors: K G Kuhn, M Torpdahl, C Frank, K Sigsgaard, S Ethelberg
Journal: Eurosurveillance (2011)

Between April and June 2010, a small national outbreak of Salmonella Typhimurium with a particular multilocus variable-number tandem repeat analysis (MLVA) type was identified in Denmark through laboratory-based surveillance. The outbreak involved twenty cases, primarily living within the greater Copenhagen area. Half of the cases were children aged ten years or younger and 12 were male; three cases were hospitalised.A matched case-control study showed a strong link between illness and eating a particular salami product containing pork and venison, matched odds ratio(mOR):150, confidence interval (CI): 19–1,600. The salami had been produced in Germany. Microbiological confirmation in food samples was sought but not obtained. Danish consumers were notified that they should return or dispose of any packages from the suspected salami batch. Because the salami product had potentially been sold in other European countries, the European Centre for Disease Prevention and Control urgent enquiry and Rapid Alert System for Food and Feed systems were used to highlight the possibility of outbreaks in these countries. Case-control studies area strong tool in some outbreak investigations and evidence from such studies may give sufficient information to recall a food product.
Chronic Hypoxia Accentuates Dysanaptic Lung Growth
Authors: Conrado J. Llapur, Myriam R. Martínez, Pedro T. Grassino, Ana Stok, Héctor H. Altieri, Federico Bonilla, María M. Caram, Natasha M. Krowchuk, Miranda Kirby, Harvey O. Coxson, Robert S. Tepper
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Adults born and raised at high altitudes have larger lung volumes and greater pulmonary diffusion capacity compared with adults at low altitude; however, it remains unclear whether the air and tissue volumes have comparable increases and whether there is a difference in airway size.To assess the effect of chronic hypoxia on lung growth using in vivo high-resolution computed tomography measurements.Healthy adults born and raised at moderate altitude (2,000 m above sea level; n = 19) and at low altitude (400 m above sea level; n = 23) underwent high-resolution computed tomography. Differences in total lung, air, and tissue volume, mean lung density, as well as airway lumen and wall areas in anatomically matched airways were compared between groups.No significant differences for age, sex, weight, or height were found between the two groups (P > 0.05). In a multivariate regression model, altitude was a significant contributor for total lung volume (P = 0.02), air volume (P = 0.03), and tissue volume (P = 0.03), whereby the volumes were greater for the moderate- versus the low-altitude group. However, altitude was not a significant contributor for mean lung density (P = 0.35) or lumen and wall areas in anatomically matched segmental, subsegmental, and subsubsegmental airways.Our findings suggest that the adult lung did not increase lung volume later in life by expansion of an existing number of alveoli, but rather from increased alveolarization early in life. In addition, chronic hypoxia accentuates dysanaptic lung growth by increasing the lung parenchyma but not the airways.
Similar quit rates are found with three smoking cessation options
Authors: Jacqui Wise
Journal: BMJ (2016)

The drug varenicline (Champix) was found to be no better than combination nicotine replacement therapy or a standard nicotine patch in helping adults to stop smoking in the long term, a randomised controlled trial published in JAMA has shown.1

The researchers said that their open label study was the first to contrast varenicline and combination nicotine replacement therapies directly, both with one another and with the nicotine patch. Such a comparison …
Costs associated with intravenous (IV) chemotherapy administration in patients with lung cancer
Authors: A. T. Skarin, M. S. Duh, J. R. Weiner, P. Lefebvre, M. P. Neary
Journal: Journal of Clinical Oncology (2007)

18092 Background: The IV method of chemotherapy administration imposes not only a time burden on patients and facilities, but also has cost implications for payers. This study aims to assess the costs associated with the IV administration of chemotherapies for patients with all forms of lung cancer and for a subset of patients with small cell lung cancer (SCLC) in a large employer-payer claims database. Methods: Using medical claims data from 5.5 million beneficiaries between 01/01/1998 and 01/31/2006, we identified 8,605 patients with lung cancer (ICD-9 codes 162.3–162.9, 176.4, or 197.0) receiving IV chemotherapies. We then identified a subset of 942 patients likely to have SCLC by selecting those receiving chemotherapy regimens primarily used to treat SCLC and excluding patients receiving procedures and treatments often associated with NSCLC. Average total costs per day of IV chemotherapy administration (including drug, administration costs, etc.) were computed for all patients and for the SCLC subset based on the actual amount paid. Costs were also computed separately for: IV chemotherapy drugs, IV chemotherapy administration procedures, and other drugs and services such as IV administration of other drugs to treat side effects of chemotherapies, evaluation and management, and laboratory tests. Results: Average total cost per day of IV chemotherapy administration for all patients was $1,112, with $652 (59%) attributable to IV chemotherapy drugs, $85 (8%) to IV chemotherapy administration procedures, and $375 (34%) to other drugs and services. Among patients with SCLC, average total daily cost was $815, with $423 (52%) attributable to IV chemotherapy drugs, $89 (11%) to IV chemotherapy administration, and $303 (37%) to other drugs and services. Conclusions: IV chemotherapy administration procedures and other visit-related services accounted for 42% and 48% of total costs in patients with all forms of lung cancer and those with SCLC, respectively. The increased availability and use of oral chemotherapy drugs in lung cancer should provide savings to payers by avoiding the costs associated with IV administration. No significant financial relationships to disclose.
Prognostic factors in aggressive lymphoma.
Authors: W S Velasquez
Journal: Journal of Clinical Oncology (1991)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1991.9.7.1320 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2045872 Prognostic factors in aggressive lymphoma. W S VelasquezxW S VelasquezSearch for articles by this author https://doi.org/10.1200/JCO.1991.9.7.1320 PDF "Prognostic factors in aggressive lymphoma.." Journal of Clinical Oncology, 9(7), pp. 1320–1321© 1991 by American Society of Clinical Oncology